Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Gynecologic 1

Conditions

Fallopian Tube Neoplasms 10Ovarian Neoplasms 7Endometrial Neoplasms 5Breast Neoplasms 4Prostatic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Osteosarcoma 2Neuroendocrine Tumors 2Neuroblastoma 2Neoplasms 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Glioma 2Ependymoma 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Recurrence 1

Interventions

Carboplatin 13pembrolizumab 12Specimen Handling 9Paclitaxel 5Magnetic Resonance Spectroscopy 5Capecitabine 5Biopsy 5Nivolumab 4Cyclophosphamide 4sacituzumab govitecan 3Gemcitabine 3Fulvestrant 3olaparib 2fludarabine 2atezolizumab 2aldesleukin 2Taxes 2Letrozole 2Epirubicin 2Docetaxel 2Cisplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2zimberelimab 1veliparib 1trastuzumab deruxtecan 1toripalimab 1sintilimab 1pyrotinib 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × olaparib × 30 days × Clear all
NCT06966700 2026-06-01

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Merck Sharp & Dohme LLC

Phase 3 Recruiting
2,400 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01116648 2026-05-28

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
155 enrolled 34 charts
BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡